Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
biomarker
brain metastases
ovarian cancer
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
03 12 2021
03 12 2021
Historique:
received:
29
09
2021
revised:
26
11
2021
accepted:
29
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
5
1
2022
Statut:
epublish
Résumé
Epithelial ovarian cancer (EOC) is the leading cause of death among women affected by gynaecological malignancies. Most patients show advanced disease at diagnosis (FIGO stage III-IV) and, despite the introduction of new therapeutic options, most women experience relapses. In most cases, recurrence is abdominal-pelvic; however, EOC can occasionally metastasize to distant organs, including the central nervous system. The incidence of brain metastases (BMs) from EOC is low, but it has grown over time; currently, there are no follow-up strategies available. In the last decade, a few biomarkers able to predict the risk of developing BMs from OC or as potential therapeutic targets have been investigated by several authors; to date, none have entered clinical practice. The purpose of this review is to offer a summary on the role of the most relevant predictors of central nervous system (CNS) involvement (hormone receptors; BRCA; MRD1; PD-1/PD-L1) and to highlight possible therapeutic strategies for the management of metastatic brain disease in EOC.
Identifiants
pubmed: 34943916
pii: cells10123408
doi: 10.3390/cells10123408
pmc: PMC8699445
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Gynecol Oncol Rep. 2016 Oct 19;18:22-24
pubmed: 27819019
J Obstet Gynaecol Res. 2019 Mar;45(3):743-747
pubmed: 30565790
J Obstet Gynaecol Res. 2013 Jan;39(1):292-6
pubmed: 22889437
Adv Med Sci. 2019 Sep;64(2):235-240
pubmed: 30822630
Cancers (Basel). 2020 Jun 22;12(6):
pubmed: 32580290
Ann Oncol. 2018 Jun 1;29(6):1366-1376
pubmed: 29750420
Cancer Lett. 2006 Jan 18;231(2):151-7
pubmed: 16399219
Diagnostics (Basel). 2020 Mar 07;10(3):
pubmed: 32156035
Cancers (Basel). 2019 Jul 24;11(8):
pubmed: 31344859
Clin Med Insights Oncol. 2016 Mar 29;10:17-25
pubmed: 27053923
Obstet Gynecol. 2000 Sep;96(3):417-21
pubmed: 10960636
BMJ Case Rep. 2019 Aug 28;12(8):
pubmed: 31466953
Gynecol Oncol. 2018 Jan;148(1):79-85
pubmed: 29157627
Gynecol Oncol. 2019 Jun;153(3):568-573
pubmed: 30876674
Gynecol Oncol. 2012 Jun;125(3):661-6
pubmed: 22406638
Gynecol Oncol. 2004 Apr;93(1):98-106
pubmed: 15047220
Immunotherapy. 2016 Oct;8(10):1193-204
pubmed: 27605068
Br J Cancer. 2016 Aug 9;115(4):431-41
pubmed: 27415012
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Int J Gynecol Cancer. 2011 Jul;21(5):816-21
pubmed: 21613959
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Ann Transl Med. 2019 Dec;7(Suppl 8):S276
pubmed: 32015995
Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7
pubmed: 29232467
Br J Cancer. 2009 Dec 1;101(11):1919-24
pubmed: 19826419
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Gynecol Oncol. 2015 May;137(2):343-50
pubmed: 25725131
Gynecol Oncol. 2012 Jun;125(3):677-82
pubmed: 22406760
Am J Surg Pathol. 2007 Feb;31(2):161-9
pubmed: 17255760
Arch Gynecol Obstet. 2016 Jun;293(6):1161-8
pubmed: 26861465
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Cancer Lett. 2016 Jan 1;370(1):153-64
pubmed: 26499806
Gynecol Oncol. 2012 Apr;125(1):37-41
pubmed: 22198245
Ann Oncol. 2017 Nov 1;28(suppl_8):viii8-viii12
pubmed: 29232468
Neuropathology. 2015 Apr;35(2):122-9
pubmed: 25377896
Ann Oncol. 2017 Nov 1;28(suppl_8):viii13-viii15
pubmed: 29232469
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
J Neurooncol. 2004 Feb;66(3):313-25
pubmed: 15015663
J Clin Oncol. 2010 May 20;28(15):2505-11
pubmed: 20406939
PLoS One. 2012;7(9):e44787
pubmed: 22970307
Pathol Res Pract. 2019 Aug;215(8):152404
pubmed: 30962002
Gynecol Oncol. 2013 Feb;128(2):198-203
pubmed: 23142074
Cancer. 2011 Jun 1;117(11):2505-12
pubmed: 24048799
J Neurooncol. 2005 Oct;75(1):5-14
pubmed: 16215811
Int J Gynecol Cancer. 2019 Jan;29(1):201-211
pubmed: 30640705
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759682
Am J Clin Oncol. 2011 Oct;34(5):488-93
pubmed: 20921883
Expert Rev Anticancer Ther. 2017 Feb;17(2):109-117
pubmed: 27967255
Histopathology. 2014 Jun;64(7):1004-13
pubmed: 24329781
PLoS One. 2016 Nov 3;11(11):e0166058
pubmed: 27812204
Cancers (Basel). 2021 Feb 17;13(4):
pubmed: 33671294
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Oncol. 2018 Feb 05;8:16
pubmed: 29459887
Int J Mol Sci. 2021 Apr 19;22(8):
pubmed: 33921561
Oncotarget. 2018 Dec 14;9(98):37080-37096
pubmed: 30647846
Oncotarget. 2017 May 30;8(57):97657-97670
pubmed: 29228641
Front Oncol. 2020 Mar 25;10:361
pubmed: 32269964
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208030
Oncoimmunology. 2018 Sep 6;7(12):e1499388
pubmed: 30524890
Int J Mol Sci. 2021 Jul 20;22(14):
pubmed: 34299364
Oncology (Williston Park). 2016 Feb;30(2):166-76
pubmed: 26892153
J Ovarian Res. 2020 May 4;13(1):53
pubmed: 32366278
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Lancet Oncol. 2021 Sep;22(9):1275-1289
pubmed: 34363762
Gynecol Oncol. 2018 Sep;150(3):460-465
pubmed: 30001833
Cancer. 1985 Sep 1;56(5):1209-13
pubmed: 4016709
Oncotarget. 2017 Jun 20;8(25):41143-41153
pubmed: 28467804
Expert Rev Neurother. 2004 Jul;4(4):633-40
pubmed: 15853582
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Steroids. 2017 Feb;118:93-108
pubmed: 28041951
Cancers (Basel). 2019 Mar 23;11(3):
pubmed: 30909618
Clin Cancer Res. 2019 May 1;25(9):2737-2744
pubmed: 30647078
Gynecol Oncol. 2019 Feb;152(2):278-285
pubmed: 30501904
Onco Targets Ther. 2020 Dec 18;13:12979-12986
pubmed: 33376347
Ann Oncol. 2020 Sep;31(9):1148-1159
pubmed: 32569725
Mol Endocrinol. 2008 Sep;22(9):2085-98
pubmed: 18550773
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227
Diagnostics (Basel). 2019 Aug 01;9(3):
pubmed: 31374917
Mol Clin Oncol. 2020 Jul;13(1):73-75
pubmed: 32454976
Theranostics. 2021 Mar 11;11(11):5330-5345
pubmed: 33859750
Drug Resist Updat. 2015 Jan;18:1-17
pubmed: 25554624
Curr Opin Obstet Gynecol. 2020 Feb;32(1):1-8
pubmed: 31833942
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Anticancer Res. 2005 Sep-Oct;25(5):3553-8
pubmed: 16101179
Am J Surg Pathol. 2011 Jun;35(6):816-26
pubmed: 21552115
Int J Mol Sci. 2020 Dec 27;22(1):
pubmed: 33375467
Am J Pathol. 2021 Jan;191(1):26-39
pubmed: 33011111
Lancet Oncol. 2021 Jul;22(7):1034-1046
pubmed: 34143970
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Lancet Oncol. 2019 Apr;20(4):470-472
pubmed: 30880068
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Recent Pat Anticancer Drug Discov. 2018;13(4):392-410
pubmed: 29512470
Cancer. 2004 Mar 1;100(5):999-1007
pubmed: 14983496
J Neurooncol. 2014 Aug;119(1):1-6
pubmed: 24789253
Gynecol Oncol. 2019 Jul;154(1):144-149
pubmed: 31113680
Nat Immunol. 2013 Dec;14(12):1212-8
pubmed: 24240160
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Hum Cell. 2013 Jun;26(2):56-66
pubmed: 23504277
Cells. 2020 May 15;9(5):
pubmed: 32429133
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455819
Cancer Immunol Immunother. 2021 Oct;70(10):2951-2960
pubmed: 33713153
Gynecol Oncol. 2016 Dec;143(3):532-538
pubmed: 27717490
Front Pharmacol. 2013 Nov 04;4:136
pubmed: 24312053